Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 28;7(1):287–304. doi: 10.3390/cancers7010287

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

FDG-PET images of an 11-year-old male patient with mixed cellularity HL stage II at staging (A), interim (B) and at restaging due to suspected relapse 16 months after initial diagnosis (C). (A) Lymphoma lesions at staging were found at left supra- and infraclavicular sites and in the mediastinum. The patient was treated according to the TG1 protocol (GPOH-HD2002P); (B) The interim PET demonstrated minimal residual uptake in the left mediastinum adjacent to the left atrium/ventricle primarily interpreted as physiological myocardial uptake (with no anatomical equivalent in the corresponding low-dose CT). This lesion was missed by the first truth-panel assessment (false negative by visual assessment). By semi-quantitative means the lesion exceeded SUV thresholds (true positive by semi-quantitative means); (C) PET at time point of restaging showed multiple areas of intense tracer uptake indicating a recurrence.